Asia-Pacific HIV Clinical Forum 2021
Related Enduring Materials
14 June | Day 1
15 June | Day 2
In Memoriam: Dr. Charles Boucher
We are deeply saddened to share that Dr. Charles Boucher, a Program Director of the European HIV Clinical Forum 2021, has passed away after a courageous battle with cancer. Read our full memorial >
The Asia-Pacific HIV Clinical Forum 2021 provided an independent scientific program involving the world’s leading experts and is specifically designed for HIV healthcare professionals in the Asia-Pacific region and focuses on optimizing treatment for their patients.
This program featured challenging plenary lectures followed by ample time for Q&A and debate, stimulating interaction, and the sharing of knowledge within the HIV-treating community. The program included virtual networking opportunities for community building providing delegates with the unique opportunity to meet their colleagues in a focused and scientific setting.
The HIV Clinical Forum is a series of interactive programs that provide an independent scientific program on emerging topics in HIV, involving experts where HIV clinicians and allied healthcare professionals receive updates on the latest developments related to HIV management, where they can share their clinical experience and present results from their ongoing and completed cohorts/research programs.
Furthermore, the HIV Clinical Forum provides an educational setting where healthcare professionals can acquire specific skills that will enhance their capabilities to interpret research results and even develop new research projects.
Program Directors
General Information
We are available to answer any questions or concerns that you may have about your participation at the Asia-Pacific HIV Clinical Forum 2021: Optimizing Treatment. For more information, please contact Ms. Kate Kolchina at kate.kolchina@amededu.com.
To stay updated on developments about this meeting, make sure that you are signed up for our newsletter.
Secondary: Researchers
Tertiary: Healthcare workers, clinical virologists, microbiologists, scientists, pharmacologists, nurses, post-doctoral researchers, students, and other healthcare professionals involved in treating people living with HIV.
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients;
- Create a platform for interactive information exchange on novel treatment options; and
- Translate the latest research achievements into clinical guidance for the optimal management of individuals living with HIV.
- Understand the clinical data supporting novel treatment strategies;
- Describe the pros and cons of novel treatment strategies;
- Understand how to integrate novel treatment strategies into routine patient care;
- Be knowledgeable of the clinical data supporting long-acting injectable regimens;
- Identify patients who might best benefit from long acting injectable regimens;
- Know how best to integrate injectable drugs in to routine clinical care;
- Improve their skills in defining and identifying complex HIV patients;
- Stay informed on new drug options for complex patients; and
- Understand how best to use new treatment options in complex HIV patients.
Practical Information
We trust that the following information (in alphabetical order) will assist you in organizing your participation in the Asia-Pacific HIV Clinical Forum 2021: Optimizing Treatment.
Program Directors
Local Chair
The Program Chairs are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the forum meeting, identify interesting topics and candidate speakers, and review all submitted abstracts.
The Online Asia-Pacific HIV Clinical Forum 2021 is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Resources
Hear about new treatment options and join Dr. Kiat Ruxrungtham in his lecture as he explores switching patients to reduced drug regimens.
Read this article for further insights into switching to Dolutegravir based regimens: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621926/
